Assessment of Oxycodone and Mebeverin mixed-effects on colonoscopy quality

Assessment of Oxycodone and Mebeverin mixed-effects on colonoscopy quality in patients referring to Urmia Imam Khomeini hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201204049599N3

Enrollment

125

Registered

2021-04-22

Start date

2021-04-30

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colonoscopy. Gastrointestinal hemorrhage, unspecified

Interventions

Intervention 1: Intervention group: One hour before colonoscopy, patients in this group will be given 15 mg of oral Oxycodone tablet and 270 mg of oral Mebeverine capsule . Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Do not take antispasmodics Suspicion of intestinal polyps bowel diseases Unknown gastrointestinal bleeding

Exclusion criteria

Exclusion criteria: Irritable Bowel Syndrome Previous abdominal surgeries Lack of mental health and full consciousness Allergy to oxycodone Allergy to Mebeverine Taking anti-anxiety and painkillers History of allergy to any drug

Design outcomes

Primary

Measure	Time frame
Total procedure time. Timepoint: During endoscopy. Method of measurement: minute, clock.;Pain. Timepoint: During endoscopy. Method of measurement: Score based on visual analog scale.;Time to reach Cecum. Timepoint: During endoscopy. Method of measurement: minute , clock.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Pashaee

Oroumia University of Medical Sciences

pashaee.m@umsu.ac.ir+98 44 3198 8001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026